Targeted Therapy Reverses Weight Gain From Rare Cause of Obesity
In a randomized trial, the MC4R agonist setmelanotide reduced BMI and hunger in patients with acquired hypothalamic obesity. After 1 year, participants lost 36.4 lb with setmelanotide but gained 5.3…

